Natera, Inc. (NTRA)
| Market Cap | 9.91B |
| Revenue (ttm) | 391.01M |
| Net Income (ttm) | -229.74M |
| Shares Out | 81.01M |
| EPS (ttm) | -2.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $116.09 |
| Previous Close | $108.76 |
| Change ($) | 7.33 |
| Change (%) | 6.74% |
| Day's Open | 115.08 |
| Day's Range | 108.29 - 123.78 |
| Day's Volume | 1,436,689 |
| 52-Week Range | 16.87 - 127.19 |
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N), a supplier of vegetarian meat substitutes, sports and energy bars, and hemp-based products, has appealed the Federal Cou...
Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 93.48% year over year to ($0.89), which missed the ...
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $NTRA #PrecisionOncology--Natera and Personalis Partner for Personalized Monitoring in Oncology
Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on Inve...
SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual P...
SAN CARLOS, Calif., Jan. 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-...
SAN CARLOS, Calif., Jan. 14, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Pro...
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalize...
These winners are positioned for gains even after COVID.
SAN CARLOS, Calif., Jan. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at ...
SAN CARLOS, Calif., Dec. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office gra...
Increased adoption and expansion of products resulting in significant rises in volume. Producing meaningful improvements in revenues and costs per unit.
SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United S...
SAN CARLOS, Calif., Nov. 30, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of Oncology,...
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.
SAN CARLOS, Calif., Nov. 12, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the ...
In this article we will take a look at whether hedge funds think Natera Inc (NASDAQ:NTRA) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving ...
SAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on i...
Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call Transcript
Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN CARLOS, Calif., Oct. 30, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prena...
SAN CARLOS, Calif., Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third ...
SAN CARLOS, Calif., Oct. 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that a major health plan has extended cover...
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN CARLOS, Calif., Oct. 8, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Centene, a major healthcare insurance c...
SAN CARLOS, Calif. and LOS ANGELES, Oct. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has teamed up with the George Lo...
SAN CARLOS, Calif., Oct. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reports that the U.S. District Court of Delaware has r...
SAN CARLOS, Calif., Oct. 2, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) ...
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Natera (NTRA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
SAN CARLOS, Calif., Sept. 24, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program...
SAN CARLOS, Calif., Sept. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personaliz...
For this report, we analyzed the portfolios of the 13 small-cap growth investment managers with the best 10-year performance records.
SAN CARLOS, Calif., Sept. 14, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 9, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 3, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Sept. 1, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Aug. 27, 2020 /PRNewswire/ -- Natera, Inc.
Natera shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stock Upgrades: Natera Shows Rising Relative Strength appeared first on Investor's Busi...
SAN CARLOS, Calif., Aug. 18, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif., Aug. 7, 2020 /PRNewswire/ -- Natera, Inc.
Natera, Inc. (NTRA) CEO Steve Chapman on Q2 2020 Results - Earnings Call Transcript
Natera (NTRA) delivered earnings and revenue surprises of -21.05% and 17.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN CARLOS, Calif., Aug. 5, 2020 /PRNewswire/ -- Natera, Inc.
About NTRA
Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 2, 2015 |
| Stock Exchange NASDAQ | Ticker Symbol NTRA |
Financial Performance
In 2020, Natera's revenue was $391.01 million, an increase of 29.33% compared to the previous year's $302.33 million. Losses were -$229.74 million, 84.0% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for Natera stock is "Strong Buy." The 12-month stock price forecast is 122.78, which is an increase of 5.76% from the latest price.